Globally Resilient Supply Chains
for Seasonal and Pandemic
Influenza Vaccines
Ravi Anupindi, Prashant Yadav, Kenisha M. P. Jefferson, and
Elizabeth Ashby, Editors
Committee on Addressing Issues of Vaccine Distribution and Supply
Chains to Advance Pandemic and Seasonal Influenza Preparedness and
Response
Board on Global Health
Health and Medicine Division
A Consensus Study Report of
THE NATIONAL ACADEMIES PRESS
Washington, DC
www.nap.edu
THE NATIONAL ACADEMIES PRESS 500 Fifth Street, NW, Washington, DC 20001
This activity was supported by a contract between the National Academy of Sciences and the Office of Global Affairs with the U.S. Department of Health and Human Services. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
International Standard Book Number-13: 978-0-309-08915-9
International Standard Book Number-10: 0-309-08915-8
Digital Object Identifier: https://doi.org/10.17226/26285
Library of Congress Catalog Number: 2021951358
Additional copies of this publication are available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.
Copyright 2022 by the National Academy of Sciences. All rights reserved.
Printed in the United States of America
Suggested citation: National Academies of Sciences, Engineering, and Medicine. 2022. Globally resilient supply chains for seasonal and pandemic influenza vaccines. Washington, DC: The National Academies Press. https://doi.org/10.17226/26285.
The National Academy of Sciences was established in 1863 by an Act of Congress, signed by President Lincoln, as a private, nongovernmental institution to advise the nation on issues related to science and technology. Members are elected by their peers for outstanding contributions to research. Dr. Marcia McNutt is president.
The National Academy of Engineering was established in 1964 under the charter of the National Academy of Sciences to bring the practices of engineering to advising the nation. Members are elected by their peers for extraordinary contributions to engineering. Dr. John L. Anderson is president.
The National Academy of Medicine (formerly the Institute of Medicine) was established in 1970 under the charter of the National Academy of Sciences to advise the nation on medical and health issues. Members are elected by their peers for distinguished contributions to medicine and health. Dr. Victor J. Dzau is president.
The three Academies work together as the National Academies of Sciences, Engineering, and Medicine to provide independent, objective analysis and advice to the nation and conduct other activities to solve complex problems and inform public policy decisions. The National Academies also encourage education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science, engineering, and medicine.
Learn more about the National Academies of Sciences, Engineering, and Medicine at www.nationalacademies.org.
Consensus Study Reports published by the National Academies of Sciences, Engineering, and Medicine document the evidence-based consensus on the study’s statement of task by an authoring committee of experts. Reports typically include findings, conclusions, and recommendations based on information gathered by the committee and the committee’s deliberations. Each report has been subjected to a rigorous and independent peer-review process, and it represents the position of the National Academies on the statement of task.
Proceedings published by the National Academies of Sciences, Engineering, and Medicine chronicle the presentations and discussions at a workshop, symposium, or other event convened by the National Academies. The statements and opinions contained in proceedings are those of the participants and are not endorsed by other participants, the planning committee, or the National Academies.
For information about other products and activities of the National Academies, please visit www.nationalacademies.org/about/whatwedo.
COMMITTEE ON ADDRESSING ISSUES OF VACCINE DISTRIBUTION AND SUPPLY CHAINS TO ADVANCE PANDEMIC AND SEASONAL INFLUENZA PREPAREDNESS AND RESPONSE
RAVI ANUPINDI (Chair), Colonel William G. and Ann C. Svetlich Professor of Operations Research and Management, University of Michigan
PRASHANT YADAV (Vice Chair), Senior Fellow, Center for Global Development; Affiliate Professor, INSEAD, France; Lecturer, Harvard Medical School
MAHSHID ABIR, Senior Policy Researcher, RAND Corporation; Associate Professor, University of Michigan Medical School
RICK A. BRIGHT, Senior Vice President, Pandemic Prevention and Response, The Rockefeller Foundation
WILLIAM G. BUREL, President and Chief Executive Officer, Hamilton Grace, LLC
MATTHEW DOWNHAM, Sustainable Manufacturing Lead, Coalition for Epidemic Preparedness Innovations
NAGWA HASANIN, Senior Health Advisor, UNICEF
NOREEN A. HYNES, Associate Professor, Johns Hopkins University Schools of Medicine and Public Health
DAVID C. KASLOW, Chief Scientific Officer, PATH
PINAR KESKINOCAK, William W. George Chair and Professor and Director, Center for Health and Humanitarian Systems, Georgia Institute of Technology
SAAD B. OMER, Director, Yale Institute for Global Health
JENNIFER PANCORBO, Director of Industry Programs and Research, Biomanufacturing Training and Education Center, North Carolina State University
Study Staff
KENISHA M. P. JEFFERSON, Study Director
ELIZABETH ASHBY, Research Associate
EMILIE RYAN-CASTILLO, Senior Program Assistant
CLAIRE BIFFL, Senior Program Assistant
PATRICIA A. CUFF, Senior Program Officer
JULIE A. PAVLIN, Senior Director, Board on Global Health
Consultants
JOSEPH ALPER, Science Writer (until July 2021)
KEVIN FAHEY, Science Writer (from August 2021)
EUGENIA GROHMAN, Editor (from July 2021)
MELISSA MAITIN-SHEPARD, Science Writer (from July 2021)
JANAMARIE PERROUD, Technical Writer
Reviewers
This Consensus Study Report was reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise. The purpose of this independent review is to provide candid and critical comments that will assist the National Academies of Sciences, Engineering, and Medicine in making each published report as sound as possible and to ensure that it meets the institutional standards for quality, objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process.
We thank the following individuals for their review of this report:
Although the reviewers listed above provided many constructive comments and suggestions, they were not asked to endorse the conclusions or recommendations of this report nor did they see the final draft before its release. The review of this report was overseen by ANDY STERGACHIS,
University of Washington, and BOBBIE BERKOWITZ, Columbia University. They were responsible for making certain that an independent examination of this report was carried out in accordance with the standards of the National Academies and that all review comments were carefully considered. Responsibility for the final content rests entirely with the authoring committee and the National Academies.
National Academy of Medicine
Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response Series
This study, Globally Resilient Supply Chains for Seasonal and Pandemic Influenza Vaccines, provides recommendations on how to bolster vaccine distribution and enhance global vaccine development and manufacturing infrastructure for pandemic and seasonal influenza events, using lessons learned from COVID-19. It is one of four studies conducted under the Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response Initiative, which explores how the scientific and technological breakthroughs throughout the COVID-19 pandemic could inform and advance future pandemic and seasonal influenza vaccine preparedness and response efforts.
The three companion studies to this study examine how the lessons learned from COVID-19 around vaccine research and development, public health interventions and countermeasures, and global coordination, partnerships, and financing could be best utilized to improve the development and distribution of pandemic and seasonal influenza vaccines. Together, the four consensus studies present a path toward better preparedness in addressing pandemic and seasonal influenza.
Launched by the National Academy of Medicine with support from the Office of Global Affairs, U.S. Department of Health and Human Services, the Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response Initiative acknowledges that influenza is here to stay. The unprecedented scope of this initiative allowed for international experts to look at this issue from multiple angles and provide recommendations that set out a pathway to more effective influenza vaccines worldwide. Driven by international cooperation, this independent initiative provides a platform to highlight why we need to act as a global community to better prepare for pandemic and seasonal influenza.
This page intentionally left blank.
Acknowledgments
This report is a product of the cooperation and contributions of many people, all of whom helped address a very broad statement of task in an extremely short timeframe. The committee is especially grateful to all the external experts who provided invaluable input at committee meetings. Their names and affiliations can be found in the committee meeting agendas in Appendix C. This report would not be possible without the sponsorship of the U.S. Department of Health and Human Services’ Office of Global Affairs and the support from the National Academy of Medicine’s International Committee, which was integral in conceptualizing the study’s statement of task.
The committee also thanks Leslie Sim and Taryn Young for their flexibility and coordination during the review process as well as Lauren Shern for providing guidance throughout the course of the project. A special thank you to Victor Stewart and Ron Brown for quickly processing contracts and agreements throughout the life cycle of the study.
Our acknowledgments also extend to the directors of the partner influenza studies, Ellen Schenk, Hoda Soltani, and Janelle Winters, for their unwavering support and advice during the study process.
This page intentionally left blank.
Preface
The global COVID-19 pandemic has exposed serious weaknesses in the supply chain for vaccines and medical products. Many of these challenges have been managed with reactive responses by U.S. government agencies and global actors. However, these responses cannot hide the shortcomings in the current structures for managing vaccine supply chains before and during a pandemic. The supply chain challenges, which have unfolded throughout the COVID-19 pandemic, have exposed major weaknesses in the mechanisms of global coordination.
While the world is still struggling to manage the challenges in the global COVID-19 vaccine supply chain, everyone needs to prepare for a more robust vaccine supply chain to deal with future pandemics. Global health experts have long warned of the risks of influenza variants with potential to cause a pandemic. This committee was tasked with examining the supply chain and distribution challenges related to vaccines and vaccinations during the COVID-19 response (as well as past responses to SARS, H1N1, and Ebola), identify deficiencies in the global supply chain for pandemic and seasonal influenza, and develop recommendations for action by U.S. government agencies and global actors.
Vaccine manufacturing and distribution is a complex task. It requires hundreds of components, globally distributed high-quality biologic manufacturing capacity, a competent supply chain workforce, data and information tools, and financial resources for fast distribution and equitable deployment of vaccines. At a country level, getting vaccines into the arms of people also requires country preparedness and robust planning and the capability to adopt, distribute, deliver, and administer vaccines to appropri-
ate cohorts of people at scale. Vaccine characteristics and country access to a portfolio of vaccines also influence vaccine uptake and impact the efficiency of vaccine distribution and delivery.
In a global end-to-end supply chain, actions for different parts of this supply chain are made by different agencies and actors—from private firms to national governments, regional structures, global and UN agencies, and nongovernmental organizations. COVID-19 has also illustrated the devastating impact of a pandemic on the global economy and livelihoods, which necessitates considering roles for a broader set of actors. Health care and non–health care domains can engage in the vaccine supply chain to ensure a safer world through a whole-of-society approach.
The committee’s report takes stock of past actions and reports on seasonal and pandemic influenza vaccine manufacturing and distribution, looks at experiences and structures that have evolved for COVID-19 vaccines, and identifies deficiencies in the global supply chains for seasonal and pandemic influenza vaccines and also covers country preparedness and planning capabilities that need to be urgently addressed. The report points out technical areas and structural weaknesses that need to be strengthened and lays out mechanisms to strengthen coordination and information exchange systems in the global supply chain to ensure rapid and agile decision making to meet global vaccination needs equitably.
We hope that this report will provide clear guidance on the actions required by different stakeholders, both U.S. agencies and global actors, to build a robust and resilient global end-to-end supply chain for seasonal and pandemic influenza vaccines. Pursuing the recommendations in this report will not always be easy: the split of mandate, resourcing, and decision-making processes between national, regional, and global levels creates the need for embedding collaborative and coordinate efforts in existing agencies and structures. Everyone recognizes that for vaccine supply chains to work well during a pandemic, there is need for strong collaboration and coordination between a range of national, regional, and global actors in the supply chain, both public and private actors. If there is one key message that every reader should take away from this report, it is that this committee firmly believes that for the global vaccine supply chain to work well during a pandemic, many of the activities and coordination structures in the supply chain should be designed, created, and resourced during non-pandemic periods and not during a pandemic.
We thank first the members of committee, who committed their time and scientific expertise during an extremely busy period with their multiple roles. Ours was a very interdisciplinary committee, with experts of varied backgrounds in many different aspects of vaccine development, manufacturing, distribution, and policy. The committee members exhibited immense
patience and respect when discussing items, which for some were relatively straightforward and simple, and for others were new and complex.
Thanks also to National Academies of Sciences, Engineering, and Medicine staff, who helped us stay organized and focused and helped put our thoughts into writing. They worked tirelessly through our sessions, took notes, and iterated with many draft versions of this report. We also thank Janamarie Perroud for providing an overview of previous work on this subject, which was an important foundation for framing this study (see Appendix A). We are also grateful to the many experts who committed their time to present to the committee during public sessions.
Ravi Anupindi, Chair
Prashant Yadav, Vice Chair
Committee on Addressing Issues of Vaccine Distribution and
Supply Chains to Advance Pandemic and Seasonal Influenza
Preparedness and Response
This page intentionally left blank.
Training and Readiness of Critical Workforce Personnel
Distributed Manufacturing Networks
4 VACCINE DISTRIBUTION AND DELIVERY
Demand Forecasting and Generation
Global Distribution and Transportation
In-Country Storage and Distribution
5 FRAMEWORKS, TOOLS, AND INNOVATIONS FOR DISTRIBUTION READINESS
Tools and Frameworks for Global Vaccination
Tools for Country Pandemic Preparedness
6 BARRIERS, INCENTIVES, AND INNOVATIONS FOR SUSTAINABLE MANUFACTURING
Tradeoffs in Vaccine Development and Manufacturing
Barriers to Vaccine Manufacturing and Innovation
Facilitating Manufacturing Innovation
Vaccine Technologies and Innovations
An Integrated Approach Across the Vaccine Landscape
A REVIEW OF PREVIOUS RECOMMENDATIONS FOR PANDEMIC VACCINE MANUFACTURING
Boxes, Figures, and Tables
BOXES
2-1 Adjuvants for Influenza Vaccines
3-1 The Defense Production Act
3-2 COVAX Marketplace for Critical Supplies
3-3 Regulatory Harmonization and Convergence for Improved Public Health
FIGURES
2-1 WHO Global Influenza Surveillance and Response System
2-2 Egg-based influenza vaccine manufacturing and timeline
2-3 Influenza vaccine response capability
2-4 Vaccine manufacturing network
3-1 Supply chain challenges along the value chain
4-1 Nations with the largest share of exports for key vaccine components and supplies in 2018
TABLES
2-1 Key Characteristics of Influenza Subtypes
2-2 Stages of and Data for Seasonal Influenza Vaccine Development and Manufacturing
2-3 Comparative Characteristics of Selected Seasonal Influenza Vaccines
2-4 Influenza Vaccine Manufacturing Facilities by WHO Region
2-5 Novel Technology Platforms for Producing Influenza Vaccines
3-1 Summary of Recommendations on Critical Components for Vaccine Manufacturing
3-2 Examples of Vaccine Manufacturing Educational Structures
4-1 Summary of Recommendations on Vaccine Distribution and Delivery
5-2 Innovations for Vaccine Development During COVID-19
6-2 Advantages and Disadvantages of Technology Platforms Used to Develop Vaccines
6-3 Non-U.S. Funding Options for No-Fault Compensation Mechanisms
6-4 Pros and Cons of Options for Housing a Vaccine Injury Compensation System
A-1 Pandemic Vaccine Manufacturing Recommendations in Chronological Order
A-2 Trends in Unimplemented Pandemic Vaccine Manufacturing Recommendations
Acronyms and Abbreviations
ACT-A | Access to COVID-19 Tools Accelerator |
ALAN | American Logistics Aid Network |
ASPR | Assistant Secretary for Preparedness and Response |
BARDA | Biomedical Advanced Research and Development Authority |
CBER | Center for Biological Evaluation and Research |
CDC | Centers for Disease Control and Prevention |
CEPI | Coalition for Epidemic Preparedness Innovations |
COVAX | COVID-19 Vaccines Global Access |
CVIC | COVID-19 Vaccine Introduction and deployment Costing tool |
CVV | candidate vaccine viruses |
DCVMN | Developing Countries Vaccine Manufacturers Network |
DPA | Defense Production Act |
EMA | European Medicines Agency |
EPI | Expanded Program on Immunization |
EUA | Emergency Use Authorization |
FDA | U.S. Food and Drug Administration |
GAO | U.S. Government Accounting Office |
GAP | Global Action Plan for Influenza Vaccines |
GAVI | Global Alliance for Vaccines and Immunization |
GISRS | Global Influenza Surveillance and Response System |
GPMB | Global Preparedness Monitoring Board |
GVAP | Global Vaccine Action Plan |
H1N1 | Influenza A virus subtype H1N1, aka swine flu |
H5N1 | Influenza A virus subtype H5N1, aka avian flu |
HHS | U.S. Department of Health and Human Services |
IA2030 | Immunization Agenda 2030 |
IFPMA | International Federation of Pharmaceutical Manufacturers & Associations |
IIV | inactivated influenza virus |
IMF | International Monetary Fund |
IPPPR | Independent Panel for Pandemic Preparedness and Response |
LAIV | live attenuated influenza virus |
LMIC | low- and middle-income country |
LMIS | logistic management information system |
LSHTM | London School of Hygiene & Tropical Medicine |
MDCK | Madin-Darby Canine Kidney |
MERS | Middle East Respiratory Syndrome |
mRNA | messenger RNA |
NIH | National Institutes of Health |
NIS-Flu | National Immunization Survey-Flu |
NITAG | National Immunization Technical Advisory Group |
NVAC | National Vaccine Advisory Committee |
OGA | Office of Global Affairs |
OWS | Operation Warp Speed |
PAHO | Pan American Health Organization |
PEPFAR | U.S. President’s Emergency Plan for AIDS Relief |
PIP | Pandemic Influenza Preparedness framework |
PIVI | Partnership for Influenza Vaccine Introduction |
TPP | Target Product Profiles |
TRIPS | Trade-Related Aspects of Intellectual Property Rights |
UNICEF | United Nations Children’s Fund |
USAID | U.S. Agency for International Development |
USTR | U.S. Trade Representative |
VIPS | Vaccine Innovation Prioritization Strategy |
VLP | virus-like particle |
WEF | World Economic Forum |
WHO | World Health Organization |
WTO | World Trade Organization |
This page intentionally left blank.